103 related articles for article (PubMed ID: 21299245)
1. Rapid and reliable measurement for evaluating directly the reactivity of N-acetylcysteine with glucose degradation products in peritoneal dialysis fluids.
Lee E; Seo EY; Kwon Y; Ha H
Anal Chem; 2011 Mar; 83(5):1518-22. PubMed ID: 21299245
[TBL] [Abstract][Full Text] [Related]
2. Glutathione depletion as a mechanism of 3,4-dideoxyglucosone-3-ene-induced cytotoxicity in human peritoneal mesothelial cells: role in biocompatibility of peritoneal dialysis fluids.
Yamamoto T; Tomo T; Okabe E; Namoto S; Suzuki K; Hirao Y
Nephrol Dial Transplant; 2009 May; 24(5):1436-42. PubMed ID: 19033251
[TBL] [Abstract][Full Text] [Related]
3. How to avoid glucose degradation products in peritoneal dialysis fluids.
Erixon M; Wieslander A; Lindén T; Carlsson O; Forsbäck G; Svensson E; Jönsson JA; Kjellstrand P
Perit Dial Int; 2006; 26(4):490-7. PubMed ID: 16881345
[TBL] [Abstract][Full Text] [Related]
4. Structure- and concentration-specific assessment of the physiological reactivity of α-dicarbonyl glucose degradation products in peritoneal dialysis fluids.
Distler L; Georgieva A; Kenkel I; Huppert J; Pischetsrieder M
Chem Res Toxicol; 2014 Aug; 27(8):1421-30. PubMed ID: 25033248
[TBL] [Abstract][Full Text] [Related]
5. 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis.
Linden T; Cohen A; Deppisch R; Kjellstrand P; Wieslander A
Kidney Int; 2002 Aug; 62(2):697-703. PubMed ID: 12110035
[TBL] [Abstract][Full Text] [Related]
6. Chemical and physiological relevance of glucose degradation products in peritoneal dialysis.
Mittelmaier S; Niwa T; Pischetsrieder M
J Ren Nutr; 2012 Jan; 22(1):181-5. PubMed ID: 22200439
[TBL] [Abstract][Full Text] [Related]
7. Identification and quantification of the glucose degradation product glucosone in peritoneal dialysis fluids by HPLC/DAD/MSMS.
Mittelmaier S; Fünfrocken M; Fenn D; Fichert T; Pischetsrieder M
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Apr; 878(11-12):877-82. PubMed ID: 20189892
[TBL] [Abstract][Full Text] [Related]
8. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
[TBL] [Abstract][Full Text] [Related]
9. Take care in how you store your PD fluids: actual temperature determines the balance between reactive and non-reactive GDPs.
Erixon M; Wieslander A; Lindén T; Carlsson O; Forsbäck G; Svensson E; Jönsson JA; Kjellstrand P
Perit Dial Int; 2005; 25(6):583-90. PubMed ID: 16411526
[TBL] [Abstract][Full Text] [Related]
10. New pH-neutral peritoneal dialysis solution, low in glucose degradation products, in a double-chamber bag.
Diaz-Buxo J; Clark SC; Ho CH; Jensen LE
Adv Perit Dial; 2010; 26():28-32. PubMed ID: 21348375
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.
Witowski J; Korybalska K; Ksiazek K; Wisniewska-Elnur J; Jörres A; Lage C; Schaub TP; Passlick-Deetjen J; Breborowicz A; Grzegorzewska A; Ksiazek A; Liberek T; Lichodziejewska-Niemierko M; Majdan M; Rutkowski B; Stompór T; Sulowicz W
Nephrol Dial Transplant; 2004 Apr; 19(4):917-24. PubMed ID: 15031350
[TBL] [Abstract][Full Text] [Related]
12. 3-Deoxygalactosone, a new glucose degradation product in peritoneal dialysis fluids: identification, quantification by HPLC/DAD/MSMS and its pathway of formation.
Mittelmaier S; Fünfrocken M; Fenn D; Pischetsrieder M
Anal Bioanal Chem; 2011 Feb; 399(4):1689-97. PubMed ID: 21136045
[TBL] [Abstract][Full Text] [Related]
13. Glucose degradation products in peritoneal dialysis: from bench to bedside.
Jörres A
Kidney Blood Press Res; 2003; 26(2):113-7. PubMed ID: 12771536
[TBL] [Abstract][Full Text] [Related]
14. 3,4-DGE is important for side effects in peritoneal dialysis what about its role in diabetes.
Ortiz A; Wieslander A; Linden T; Santamaria B; Sanz A; Justo P; Sanchez-Niño MD; Benito A; Kjellstrand P
Curr Med Chem; 2006; 13(22):2695-702. PubMed ID: 17017920
[TBL] [Abstract][Full Text] [Related]
15. Fate of the glucose degradation products 3-deoxyglucosone and glyoxal during peritoneal dialysis.
Tauer A; Bender TO; Fleischmann EH; Niwa T; Jörres A; Pischetsrieder M
Mol Nutr Food Res; 2005 Jul; 49(7):710-5. PubMed ID: 15915443
[TBL] [Abstract][Full Text] [Related]
16. Peritoneal dialysis solutions low in glucose degradation products--evidence for clinical benefits.
Tomo T
Perit Dial Int; 2008 Jun; 28 Suppl 3():S123-7. PubMed ID: 18552241
[TBL] [Abstract][Full Text] [Related]
17. 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into the peritoneal cavity cannot be found in plasma.
Erixon M; Wieslander A; Lindén T; Carlsson O; Jönsson JA; Simonsen O; Kjellstrand P
Perit Dial Int; 2009 Feb; 29 Suppl 2():S28-31. PubMed ID: 19270226
[TBL] [Abstract][Full Text] [Related]
18. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH.
Zareie M; Keuning ED; ter Wee PM; Schalkwijk CG; Beelen RH; van den Born J
Nephrol Dial Transplant; 2006 Jan; 21(1):208-16. PubMed ID: 16263741
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of an HPLC method to quantify 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids.
Frischmann M; Spitzer J; Fünfrocken M; Mittelmaier S; Deckert M; Fichert T; Pischetsrieder M
Biomed Chromatogr; 2009 Aug; 23(8):843-51. PubMed ID: 19353694
[TBL] [Abstract][Full Text] [Related]
20. Formation of advanced glycation end products during CAPD.
Tauer A; Zhang X; Schaub TP; Zimmeck T; Niwa T; Passlick-Deetjen J; Pischetsrieder M
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S57-60. PubMed ID: 12612954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
